Epidemiology of Colorectal Cancer in Inflammatory Bowel Disease – the Evolving Landscape

被引：4

作者：

Linson E.A. ^{[1
]}

Hanauer S.B. ^{[2
]}

机构：

[1] Northwestern Memorial Hospital, 250 E Huron Street, Chicago, 60611, IL

[2] Feinberg School of Medicine, Northwestern University, 676 N Saint Clair, Chicago, 60611, IL

来源：

Current Gastroenterology Reports | 2021年 / 23卷 / 9期

关键词：

Colorectal cancer; Crohn’s disease; Epidemiology of colorectal cancer; Inflammatory bowel disease; Risk of colorectal cancer; Ulcerative colitis;

D O I：

10.1007/s11894-021-00816-3

中图分类号：

学科分类号：

摘要：

Purpose of Review: To update changes in the epidemiology of colorectal cancer in patients with ulcerative colitis and Crohn’s disease over the past decades. Recent Findings: Since the mid twentieth century, studies have found that the incidence of colorectal cancer in patients with IBD has been greater than that of the general population, especially for patients with a family history of colorectal cancer, a diagnosis of primary sclerosing cholangitis, and/or pancolitis. While Crohn’s disease and ulcerative colitis are still associated with a risk of colorectal cancer, current treatment approaches and surveillance measures have markedly reduced the risk according to population-based cohort studies such that the risk is now more comparable to that of the general population. Summary: It is predicted that by 2025, more than two million patients will be living with inflammatory bowel disease in the United States. As advanced treatment options become available to achieve histologic remissions and as surveillance techniques to detect neoplasia improve, guidelines for surveillance will continue to evolve. © 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

引用

共 67 条

[1]

Ananthakrishnan A.N., Cagan A., Gainer V.S., Cheng S.C., Cai T., Szolovits P., Shaw S.Y., Churchill S., Karlson E.W., Murphy S.N., Kohane I., Liao K.P., Mortality and extraintestinal cancers in patients with primary sclerosing cholangitis and inflammatory bowel disease, J Crohn’s Colitis., 8, pp. 956-963, (2014)

[2]

Atkinson A.J., Carroll W.W., Sclerosing cholangitis. Association with regional enteritis, JAMA., 188, pp. 183-184, (1964)

[3]

Bernstein C.N., Blanchard J.F., Kliewer E., Wajda A., Cancer risk in patients with inflammatory bowel disease: a population-based study, Cancer., 91, 4, pp. 854-862, (2001)

[4]

Bonovas S., Fiorino G., Lytras T., Nikolopoulos G., Peyrin-Biroulet L., Danese S., Systematic review with meta-analysis: use of 5-aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease, Aliment Pharmacol Ther., 45, pp. 1179-1192, (2017)

[5]

Broome U., Lofberg R., Veress B., Eriksson L.S., Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential, Hepatology., 22, 5, pp. 1404-1408, (1995)

[6]

Burisch J., Jess T., Martinato M., Lakatos P.L., The burden of inflammatory disease in Europe, J Crohn’s Colitis., 7, 4, pp. 322-337, (2013)

[7]

Bye W.A., Nguyen T.M., Parker C.E., Jairath V., East J.E., Strategies for detecting colon cancer in patients with inflammatory bowel disease, Cochrane Database Syst Rev., 9, (2017)

[8]

Castano-Milla C., Chaparro M., Gisbert J.P., Systematic review with meta-analysis: the declining risk of colorectal cancer in ulcerative colitis, Aliment Pharmacol Ther., 39, 7, pp. 645-659, (2014)

[9]

Choi J.K., Kim D.W., Shin S.Y., Park E.C., Kang J.G., Effect of ulcerative colitis on incidence of colorectal cancer: results from the nationwide population-based cohort study (2003–2013), J Cancer., 7, 6, pp. 681-686, (2016)

[10]

Colombel J.F., Panaccione R., Bossuyt P., Lukas M., Baert F., Vanasek T., Et al., Effect of tight control management on Crohn’s disease (CALM): a multi-centre, randomized, controlled phase 3 trial, Lancet., 390, pp. 2779-2789, (2018)

← 1 2 3 4 5 6 7 →